260 related articles for article (PubMed ID: 12898466)
1. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
[TBL] [Abstract][Full Text] [Related]
2. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
3. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.
Gerhold DL; Liu F; Jiang G; Li Z; Xu J; Lu M; Sachs JR; Bagchi A; Fridman A; Holder DJ; Doebber TW; Berger J; Elbrecht A; Moller DE; Zhang BB
Endocrinology; 2002 Jun; 143(6):2106-18. PubMed ID: 12021175
[TBL] [Abstract][Full Text] [Related]
5. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
[TBL] [Abstract][Full Text] [Related]
7. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.
Jiang G; Dallas-Yang Q; Biswas S; Li Z; Zhang BB
Biochem J; 2004 Jan; 377(Pt 2):339-46. PubMed ID: 14556646
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Wang YL; Frauwirth KA; Rangwala SM; Lazar MA; Thompson CB
J Biol Chem; 2002 Aug; 277(35):31781-8. PubMed ID: 12082115
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.
Jiang G; Dallas-Yang Q; Li Z; Szalkowski D; Liu F; Shen X; Wu M; Zhou G; Doebber T; Berger J; Moller DE; Zhang BB
Diabetes; 2002 Aug; 51(8):2412-9. PubMed ID: 12145152
[TBL] [Abstract][Full Text] [Related]
16. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Young PW; Buckle DR; Cantello BC; Chapman H; Clapham JC; Coyle PJ; Haigh D; Hindley RM; Holder JC; Kallender H; Latter AJ; Lawrie KW; Mossakowska D; Murphy GJ; Roxbee Cox L; Smith SA
J Pharmacol Exp Ther; 1998 Feb; 284(2):751-9. PubMed ID: 9454824
[TBL] [Abstract][Full Text] [Related]
17. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
18. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
19. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
20. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
